Buttonwood Financial Advisors Inc. Cuts Stock Holdings in Solventum Co. (NYSE:SOLV)

Buttonwood Financial Advisors Inc. reduced its stake in Solventum Co. (NYSE:SOLV) by 8.8% during the 4th quarter, Holdings Channel reports. The fund owned 3,504 shares of the company’s stock after selling 336 shares during the quarter. Buttonwood Financial Advisors Inc.’s holdings in Solventum were worth $231,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Modus Advisors LLC acquired a new stake in Solventum in the 4th quarter valued at about $25,000. Copeland Capital Management LLC acquired a new stake in Solventum in the third quarter valued at approximately $26,000. Mather Group LLC. purchased a new position in Solventum in the third quarter worth approximately $27,000. Twin Lakes Capital Management LLC acquired a new position in Solventum during the 2nd quarter worth approximately $29,000. Finally, True Wealth Design LLC increased its position in shares of Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after purchasing an additional 471 shares during the last quarter.

Solventum Price Performance

Solventum stock opened at $74.93 on Monday. The stock has a 50-day simple moving average of $69.56 and a 200-day simple moving average of $66.56. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.23). The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. As a group, research analysts forecast that Solventum Co. will post 6.58 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus initiated coverage on shares of Solventum in a research note on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price for the company. Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Mizuho initiated coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective on the stock. Finally, Morgan Stanley boosted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, Solventum presently has a consensus rating of “Hold” and an average target price of $68.29.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.